171 related articles for article (PubMed ID: 26006330)
1. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.
Jain A; Jain SK
Drug Dev Ind Pharm; 2016 Jan; 42(1):136-149. PubMed ID: 26006330
[TBL] [Abstract][Full Text] [Related]
2. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
3. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
4. The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines.
Sterzyńska K; Klejewski A; Wojtowicz K; Świerczewska M; Andrzejewska M; Rusek D; Sobkowski M; Kędzia W; Brązert J; Nowicki M; Januchowski R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257426
[TBL] [Abstract][Full Text] [Related]
5. Improved Therapeutic Efficacy of Topotecan Against A549 Lung Cancer Cells with Folate-targeted Topotecan Liposomes.
Zhang J; Shi W; Xue G; Ma Q; Cui H; Zhang L
Curr Drug Metab; 2020; 21(11):902-909. PubMed ID: 32851958
[TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.
Niu R; Zhao P; Wang H; Yu M; Cao S; Zhang F; Chang J
J Drug Target; 2011 Jun; 19(5):373-81. PubMed ID: 20677917
[TBL] [Abstract][Full Text] [Related]
7. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
8. In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction.
Xiong XY; Guo L; Gong YC; Li ZL; Li YP; Liu ZY; Zhou M
Eur J Pharm Sci; 2012 Aug; 46(5):537-44. PubMed ID: 22538053
[TBL] [Abstract][Full Text] [Related]
9. In vivo pharmacokinetics, biodistribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-based polymeric micelle.
Rezazadeh M; Emami J; Hasanzadeh F; Sadeghi H; Minaiyan M; Mostafavi A; Rostami M; Lavasanifar A
Drug Deliv; 2016 Jun; 23(5):1707-17. PubMed ID: 25188785
[TBL] [Abstract][Full Text] [Related]
10. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.
Eloy JO; Petrilli R; Topan JF; Antonio HMR; Barcellos JPA; Chesca DL; Serafini LN; Tiezzi DG; Lee RJ; Marchetti JM
Colloids Surf B Biointerfaces; 2016 May; 141():74-82. PubMed ID: 26836480
[TBL] [Abstract][Full Text] [Related]
11. The enhanced longevity and liver targetability of Paclitaxel by hybrid liposomes encapsulating Paclitaxel-conjugated gold nanoparticles.
Bao QY; Zhang N; Geng DD; Xue JW; Merritt M; Zhang C; Ding Y
Int J Pharm; 2014 Dec; 477(1-2):408-15. PubMed ID: 25455782
[TBL] [Abstract][Full Text] [Related]
12. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Zucker D; Barenholz Y
J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution.
Xu Y; Meng H
Artif Cells Nanomed Biotechnol; 2016; 44(1):350-5. PubMed ID: 25162671
[TBL] [Abstract][Full Text] [Related]
14. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB
Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060
[TBL] [Abstract][Full Text] [Related]
15. PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery.
Chu B; Qu Y; Huang Y; Zhang L; Chen X; Long C; He Y; Ou C; Qian Z
Int J Pharm; 2016 Mar; 500(1-2):345-59. PubMed ID: 26794876
[TBL] [Abstract][Full Text] [Related]
16. Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity.
Patankar NA; Pritchard J; van Grinsven M; Osooly M; Bally MB
Clin Cancer Res; 2013 Feb; 19(4):865-77. PubMed ID: 23303216
[TBL] [Abstract][Full Text] [Related]
17. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
[TBL] [Abstract][Full Text] [Related]
18. Development and evaluation of well-tolerated and tumor-penetrating polymeric micelle-based dry powders for inhaled anti-cancer chemotherapy.
Rosière R; Van Woensel M; Mathieu V; Langer I; Mathivet T; Vermeersch M; Amighi K; Wauthoz N
Int J Pharm; 2016 Mar; 501(1-2):148-59. PubMed ID: 26850313
[TBL] [Abstract][Full Text] [Related]
19. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
20. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.
Tsunetoh S; Terai Y; Sasaki H; Tanabe A; Tanaka Y; Sekijima T; Fujioka S; Kawaguchi H; Kanemura M; Yamashita Y; Ohmichi M
Cancer Biol Ther; 2010 Dec; 10(11):1137-46. PubMed ID: 20935474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]